Insights On Enterprise Solutions

  1. Bio-Based Polymers Towards Net Zero In Single-Use Bioprocessing 6/13/2025

    Decarbonizing healthcare and pharmaceuticals is vital to meet climate goals and safeguard public health. Learn why these energy-intensive sectors must act swiftly to reduce emissions and navigate complex global supply chains.

  2. No Cells, No Limits To DNA Production: Inside Synthetic DNA 6/12/2025

    Here, we walk you through our groundbreaking, enzymatic DNA manufacturing process that enables the production of linear DNA templates for IVT mRNA synthesis — without the use of cells.

  3. Biomanufacturing Readiness: A Validation Model For Multiproduct Facilities 6/12/2025

    Optimize your validation strategy to meet evolving regulatory demands and product complexities with a scalable, efficient framework that accelerates facility readiness and ensures consistent quality.

  4. Minimizing Fluid Loss By Monitoring Back Pressure During Clarification 6/12/2025

    Learn how a biopharma manufacturer mitigated the significant financial risk of fluid loss with a pressure-sensing pump that now protects their high-value product during clarification operations.

  5. Comparing Serum-free To Serum-Supplemented Media 6/9/2025

    Reducing serum in vaccine manufacturing is a key consideration for lowering costs and improving supply security. We compare performance in serum-free versus serum-supplemented media.

  6. Uninstalling CTS Dynacellect Bead Removal Kit 6/9/2025

    A detailed walkthrough on how to uninstall the Gibco CTS DynaCellect Bead Removal Kit when the bead removal protocol or the Gibco CTS DynaCellect magnetic separation system is completed.

  7. 5 Key Considerations For Companies Outsourcing Process Development 6/9/2025

    Venture capital in biotech remains strong post-pandemic, especially in cell and gene therapies. Discover five key factors to help companies choose between in-house and outsourced process development strategies.

  8. Utilizing Small-Scale Downstream Studies Across Biologics Manufacturing 6/6/2025

    Small-scale downstream studies play a critical role in enabling efficient, low-risk tech transfer for biologics development.

  9. Navigating OOX Results: Effective Analysis, Management In CDMO Labs 6/5/2025

    By prioritizing the management of Out of Expectation (OOX) results within your CDMO laboratory, learn how you can ensure product integrity, patient safety, and unwavering regulatory compliance.

  10. Streamline Your mAb Manufacturing With Strategic Development And CDMO Compatibility 6/4/2025

    Though the journey to mAb development begins at lab scale, for clinical trials and commercial distribution, a production process must be streamlined and scalable to 2,000 L production and above.